A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa (REVIVE)

Chiesi

Status and phase: Enrolling; Phase 3

Conditions: Epidermolysis Bullosa, Dystrophic; Connective Tissue Disease; Congenital Abnormalities; Genetic Diseases, Inborn; Skin Diseases; Junctional Epidermolysis Bullosa; Collagen Diseases; Skin Abnormalities; Epidermolysis Bullosa, Junctional; Epidermolysis Bullosa

Treatments: Drug: Oleogel-S10

Study type: Interventional

Funder types: Industry

Identifiers

NCT06917690

CLI-FILSVAA2-01

Details and patient eligibility

About

The goal of this clinical trial is to learn if Oleogel-S10 gel works to treat skin wounds from two types of inherited epidermolysis bullosa (EB): junctional EB (JEB) or dystrophic EB (DEB) in the Japanese population. Children and adults may participate. The trial also looks at the safety of Oleogel-S10 gel. The main questions it will answer are:

• Does Oleogel-S10 gel close wounds from JEB or DEB within 45 days or reduce the size of the wounds?
• Are there any medical problems when using Oleogel-S10 gel?
• How much of the drug ends up in your blood?

The study has 2 parts. In Part 1, participants will:

• Apply Oleogel-S10 gel to the EB wound dressings at least once every 4 days for 45 days.
• Visit the clinic once every 2 weeks for checkups and tests. If participants complete Part 1, they may participate in Part 2 if they choose to. In Part 2, participants will continue to receive Oleogel-S10 gel until the product is available to buy in Japan or until the trial is stopped by the company.

Enrollment: 6 estimated patients

Sex: All

Ages: 21+ days old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female aged ≥ 21 days

2. Confirmed diagnosis of either JEB or DEB

3. Both biological parents and all 4 grandparents of Japanese descent

4. At least 3 EB wounds that meet the following criteria at the time of enrollment:

   • All are located outside of the anogenital region
   • All are distinguishable from any other wounds on the subject's body (separated by a minimum of 5 cm)
   • At least one has been present for a minimum of 21 days but less than 9 months AND is 10 cm2 to 50 cm2 in size
   • At least two have been present for a minimum of 21 days but less than 9 months AND/OR are 10 cm2 to 50 cm2 in size

5. A female subject must meet one of the following criteria:

   • If of childbearing potential, she must:

     1. Have a negative pregnancy test result at Screening and Baseline Visits, AND

     2. Agree to use one of the following highly reliable methods of contraception from the day of the informed consent signature until the day after the last Oleogel- S10 application. The following methods are acceptable:

        • Placement of an intrauterine device (IUD) or intrauterine releasing system (IUS)
        • Combined (both estrogen and progestogen) hormonal contraception (oral) associated with inhibition of ovulation, supplemented with a barrier method (preferably male condom)
        • Bilateral tubal occlusion
        • Sexual abstinence, defined as refraining from heterosexual intercourse during the entire study period
        • Partner vasectomy, provided that the partner is the sole sexual partner and has received medical verification of the surgical success

   • Be of non-childbearing potential, defined as one of the following:

     • Pre-menarche, OR
     • Post-menopausal (12 consecutive months of amenorrhea without an alternative medical cause), OR
     • Permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy (supporting evidence required)

6. Subject and/or subject's legal representative has been informed about the study, has read and understood the information provided, and has given written informed consent

7. Subject and/or subject's legal representative is able and willing to follow all study procedures and instructions

Exclusion criteria

1. Hypersensitivity to Oleogel-S10 or any of its excipients
2. Diagnosis of EB subtypes simplex or Kindler EB
3. Receipt of systemic antibiotics for wound-related infections within 7 days prior to enrollment
4. Receipt of systemic or topical (on EB wounds) steroids within 30 days prior to enrollment Exceptions: Inhaled, ophthalmic, or mucosal applications, such as budesonide suspension for esophageal strictures
5. Receipt of immunosuppressive therapy or cytotoxic chemotherapy within 60 days prior to enrollment Note: Dupilumab to manage pruritis is allowed if the subject has been on a stable dose for more than 3 months prior to baseline
6. Receipt of systemic gene therapy for the treatment of inherited EB
7. Receipt of short-acting stem cell therapy (infusion of Muse cells, allogeneic adipocyte-derived MSC sheet (topically applied), TEMCELL (allogeneic MSCs, subcutaneous injection)) within 6 months prior to study enrollment
8. Receipt of topical gene therapy for the treatment of inherited EB (e.g., beremagene geperpavec) within 3 months prior to enrollment
9. Receipt of a JACE® skin graft on any of the target wounds
10. Current and/or former malignancy, including skin malignancies such as basal cell carcinoma and squamous cell carcinoma
11. Females: Pregnant or lactating, or of childbearing potential with a fertile male partner and unwilling to use a highly reliable method of contraception from the informed consent signature until study participation ends
12. Enrollment in any other interventional study or treated with any other investigational drug for any disease within 4 weeks prior to enrollment
13. Presence of any factor in the subject and/or legal representative that could interfere with study compliance, such as the ability to attend the scheduled study visits or to properly manage the dressing changes at home

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

Oleogel-S10

Experimental group

Treatment:

Drug: Oleogel-S10